# LungMate-014 (NCT05891080)

> Neoadjuvant Therapy With Toripalimab and JS004 Combined With Platinum-based Doublet Chemotherapy for Resectable or Potentially Resectable Stage III Non-small Cell Lung Cancer: A Randomised Controlled, Open-label, Phase 2 Trial

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05891080
- Phase: PHASE2
- Status: NOT_YET_RECRUITING
- Sponsor: Shanghai Pulmonary Hospital, Shanghai, China
- Conditions: Stage III Non-small Cell Lung Cancer
- Interventions: Toripalimab; JS004; Pemetrexed; Nab-paclitaxel; Carboplatin; Surgery
- Enrollment: 124
- Primary outcome: Pathologic complete response (PCR) rate

## Indexed commentary on LungMate-014 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=lungmate-014-nct05891080